Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m(2)

AIM: The DEPICT‐1 and ‐2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin in individuals with type 1 diabetes who were receiving intensive insulin therapy. The DEPICT‐1 and ‐2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, Chantal, Dandona, Paresh, Birkenfeld, Andreas L, Hansen, Troels Krarup, Iqbal, Nayyar, Xu, John, Repetto, Enrico, Scheerer, Markus Florian, Thoren, Fredrik, Phillip, Moshe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693058/
https://www.ncbi.nlm.nih.gov/pubmed/32691513
http://dx.doi.org/10.1111/dom.14144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693058/
https://www.ncbi.nlm.nih.gov/pubmed/32691513
http://dx.doi.org/10.1111/dom.14144

Ejemplares similares